Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Finch Therapeutics Cuts 20% Workforce, Realigns Focus On C. Diff, Autism Programs

  • Finch Therapeutics Group Inc (NASDAQ:FNCH) announced the layoff of 20% of its staff in a regulatory filing. The cuts will impact 37 full-time employees.
  • The FDA in March placed a clinical hold on the Phase 3 trial for CP101, a donor-derived microbiome drug for Clostridioides difficile, as well as a partial hold on its new drug application. 
  • The FDA had asked for additional information about Finch's SARS-CoV-2 donor screening protocols. Due to the hold, the company paused enrollment in the late-stage trial, dubbed PRISM4.
  • Finch also paused its chronic hepatitis B program.
  • Finch said the restructuring would allow it to direct financial resources to the C. difficile and autism spectrum disorder programs. 
  • The changes will mean $1.1 million in costs for Finch due to severance payments and other expenses. 
  • The company said the restructuring would be substantially completed by the end of Q2.
  • Finch provided a brief update on the clinical hold of the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection, saying that the company had provided a complete response to the agency and is now awaiting feedback.
  • Price Action: FNCH shares are down 0.82% at $3.63 during the market session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.